Dr. Benjamin B.a. Bakall, MD, PhD

Dr. Bakall practices at Associated Retina Consultants, Ltd. in Phoenix, Arizona.

Dr. Bakall's NPI, 1700085222, was assigned on July 14, 2007. Dr. Bakall graduated from Uppsala University Faculty of Medicine in 2005. Dr. Bakall holds Arizona license 47552.

Dr. Bakall's primary practice is Associated Retina Consultants, Ltd., at 1750 E Glendale Ave, Phoenix, AZ 85020 in Maricopa County. The practice phone is (602) 242-4928.

Dr. Bakall's primary practice is Associated Retina Consultants, Ltd. in Phoenix, Arizona. The medical group on file is District Medical Group. Dmand AI also links Dr. Bakall to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Bakall practices, 2 sites in all. Vendor and product names are available with a free account.

Retina specialist is Dr. Bakall's primary specialty in the NPI Registry, under taxonomy code 207WX0107X. Dr. Bakall is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Bakall's licenses on file in 3 states: Arizona, Iowa and Ohio.

Dmand AI lists age-related macular degeneration, cataract, conjunctivitis, dry eye, eyelid inflammation, glaucoma, hereditary corneal conditions and hypertensive retinopathy among the conditions Dr. Bakall treats.

CMS data shows 31,030 Medicare services from Dr. Bakall across 25 procedure codes in 2024, for 1,109 Medicare patients. Medicare paid $2,450,528 for them. Every service was in an office.

CMS counts 1,109 Medicare patients who saw Dr. Bakall in 2024. The largest group is 75 to 84, with 447 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 7% are also on Medicaid. Their average risk score is 1.57, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Bakall's median patient age at 72, with 60% women.

In 2024, Dr. Bakall wrote 939 Medicare Part D claims for 288 patients. 70% of them were for generic drugs. CMS names the drug for 870 of them, across 12 drugs with 11 or more claims each, at $23,556 in total drug cost. In 2023, CMS named 796 claims across 10 drugs.

Dr. Bakall accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 18 papers to Dr. Bakall, published from 2013 to 2023. 2016 was the busiest year, with 2. The most frequent topics are Tomography, Optical Coherence, Fluorescein Angiography and Retina. Dr. Bakall has published most often in Invest Ophthalmol Vis Sci. Dr. Bakall's most frequent co-authors are Jacque L. Duncan, MD, Byron L. Lam, MD and Vinit Bharati Mahajan, MD, PhD.

CMS Open Payments shows 462 general payments to Dr. Bakall from 25 drug and device companies from 2016 to 2025. Acquisitions make up the largest share, 38% of the total. US Retina LLC paid the most, $87,675. It also lists 5 research payments totaling $2,861 in 2025.

Dr. Bakall graduated from Uppsala University Faculty of Medicine in 2005.